Abstract:The nuclear factor-E2-related factor 2 (NRF2) serves as a master regulator in cellular defense against oxidative stress and chemical detoxification. However, persistent activation of NRF2 resulting from mutations in NRF2 and/or downregulation of or mutations in its suppressor, Kelch-like ECH-associated protein 1 (KEAP1), is associated with tumorigenicity and chemoresistance of non-small-cell lung carcinomas (NSCLCs). Thus, inhibiting the NRF2-mediated adaptive antioxidant response is widely considered a promising strategy to prevent tumor growth and reverse chemoresistance in NSCLCs. Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels. In lung adenocarcinoma epithelial A549 cells, silencing of KEAP1 augmented the expression of peroxisome proliferator-activated receptor γ (PPARγ) and genes associated with cell differentiation, including E-cadherin and gelsolin. In addition, KEAP1-knockdown A549 cells displayed attenuated expression of the proto-oncogene cyclin D1 and markers for cancer stem cells (CSCs) and reduced nonadherent sphere formation. Moreover, deficiency of KEAP1 led to elevated induction of PPARγ in response to As(2)O(3). Pretreatment of A549 cells with PPARγ agonists activated PPARγ and augmented the cytotoxicity of As(2)O(3). A mathematical model was formulated to advance a hypothesis that differential regulation of PPARγ and detoxification enzymes by KEAP1 and NRF2 may underpin the observed landscape changes in chemosensitivity. Collectively, suppression of KEAP1 expression in human NSCLC cells resulted in sensitization to chemotherapeutic agents, which may be attributed to activation of PPARγ and subsequent alterations in cell differentiation and CSC abundance.

A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma

Targeting Nrf2/PHKG2 Axis to Enhance Radiosensitivity in NSCLC.

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

P1.12-07 Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

KEAP1-NRF2 pathway as a novel therapeutic target for EGFR-mutant non-small cell lung cancer

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote <i>Kras</i>/<i>Lkb1</i>/<i>Keap1</i> Mutant Lung Adenocarcinoma Cell Migration and Invasion

Transcriptional Dynamics of NRF2 Overexpression and KEAP1-NRF2 Inhibitors in Human Cell Line and Primary Lung Cells

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Perspectives on the Clinical Development of NRF2-Targeting Drugs

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy

Impact Of Nrf2 On Tumour Growth And Drug Sensitivity In Oncogenic K-Ras-Transformed Cells In Vitro And In Vivo

The RSL3 Induction of KLK Lung Adenocarcinoma Cell Ferroptosis by Inhibition of USP11 Activity and the NRF2-GSH Axis

Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.

Regulatory Role of KEAP1 and NRF2 in PPARγ Expression and Chemoresistance in Human Non-Small-cell Lung Carcinoma Cells.

Targeting tyrosine kinase inhibitor resistant non-small-cell lung cancer by inducing EGFR degradation via methionine 790 oxidation.